Non-hematopoietic essential functions of bone marrow cells: a review of scientific and clinical literature and rationale for treating bone defects

David B. Harrell,1 Eugenio Caradonna,2 Laura Mazzucco,3 Rosmarie Gudenus,4 Berthold Amann,4 Vadlov Prochazka,4 Peter V. Giannoudis,7 Christian Hendrich,8 Marcus Jäger,9 Rüdiger Krauspe,10 Philippe Hernigou11

1Harrell BioScience Consulting LLC, Quincy, MA, USA; 2Department of Cardiovascular Disease, Fondazione de Ricerca e Cura Giovanni e Paolo II, Campobasso, Italy; 3Blood Component and Regenerative Medicine Laboratory, Alessandria Hospital, Italy; 4Granzer Regulatory Consulting and Services, München, Germany; 5ASKLEPIOS Westklinikum Hamburg, Germany; 6Interventional Neuroradiology and Angiology, University of Ostrava, Czech Republic; 7Trauma and Orthopedic Surgery School of Medicine, University of Leeds, UK; 8Orthopaedische Krankenhaus Schloss Werneck, Werneck Bayern, Germany; 9Universitätsklinikum Essen, Germany; 10Klinik Orthopädische, University of Düsseldorf, Germany; 11Hôpital Henri Mondor, Creteil, France

EMA:CAT 2013 decision to use CBMA for treatment of osteonecrosis (e.g., of the femoral head) should be considered a non-ATMP. This paper is intended to provide discussion on the 20 June 2014 reflection paper by reviewing two non-hematopoietic essential functions of bone marrow cells. Additionally, we provide clinical and scientific rationale for treating osteonecrosis with CBMA.

Introduction

According to section 2.2.3. number 2 of the EMA:CAT 20 June 2014 reflection paper, marrow cells that are aspirated, centrifuged, and re-administered to fulfill their same essential function will generally be regarded as homologous use. In case no substantial manipulation of the cells takes place, the classification is based on the essential function of the cells. Such non-substantially manipulated cells used for the same essential function are not considered ATMPs. However, in section 2.3.1 it is stated that products once considered a non-ATMP have been classified as an ATMP. As an example, it is specifically listed that injection of concentrated bone marrow at the site of bone injury with the aim of healing a bone lesion can be considered as non-homologous use. According to EU Regulation 1394/2007 a tissue engineered product (an ATMP) is defined as one that consists of cells or tissues that have been subject to i) substantial manipulation, or ii) are not intended for the same essential function(s) in the recipient and the donor. Since, bone marrow aspirate is centrifuged to produce concentrated bone marrow aspirate (CBMA), it is not substantial manipulation. Such work can be considered as non-homologous use.

In this paper, we review data demonstrating that bone marrow cells, in addition to hematopoiesis, have the essential functions of osteoinduction and angiogenesis/vasculogenesis. As essential functions, to utilize bone marrow cells for treating bone defects represents a homologous use of the cells. With autologous CBMA, the donor and the recipient are the same individual. The homologous use of the cells is preserved by aspirating bone marrow in order that the acquired bone marrow stem and progenitor cells will form the native tissue of the environment in which they are placed via the normal physiological functions of autocrine and paracrine activity.

Two essential non-hematopoietic functions of bone marrow cells

Hematopoiesis is a crucial function of bone marrow cells. The bone marrow hematopoietic compartment produces approximately 500 billion cells per day that use the bone marrow vasculature as a conduit to the systemic circulation. Such high cellular turnover demands

doi:10.4081/or.2015.5691
upon the bone marrow hematopoietic system certainly demonstrate the importance of the function of hematopoiesis of bone marrow. However, hematopoiesis is not the sole function of bone marrow cells.

It is well recognized and described in the literature that bone marrow is responsible for tissue/bone repair as well as enhancing neo-vascularization. In 1997, it was first demonstrated that CD34+ cells (human hematopoietic stem and progenitor cells are both CD34+ cells) are the precursors to osteoblasts.18 Recently, it was found that a single bone marrow cell contributed to hematopoietic reconstitution and drives robust osteopoiesis.20 In this same study, it was found that long-term repopulating HSCs yield progeny that differentiate into osteoblasts following bone marrow transplantation (BMT). Therefore, a means for hematopoietic and osteopoietic maintenance was found involving cells historically thought active in hematopoiesis but not osteopoiesis. Moreover, bone marrow is home to mesenchymal stromal cells (MSCs) that do not directly contribute to blood cell production. Limiting the essential function of bone marrow cells to hematopoiesis alone does not acknowledge the functions of MSCs.

Osteopoietic potential

Within bone marrow, there is significant heterogeneity. Three main regenerative cell types exist in bone marrow: HSCs, MSCs, and endothelial progenitor cells (EPCs).29 MSCs, also called skeletal stem/progenitor cells or medicinal signaling cells,21-25 do not directly contribute to hematopoietic reconstitution. CBMA MSC population placed into osteogenic media demonstrated osteoblastic differentiation in the same manner as commercially available MSCs (Figure 2).

In 1869, it was first documented that bone marrow cells have osteogenic potential.2 It is well known that donor-derived osteopoiesis in both mice and humans occurs following BMT, even from a single bone marrow cell. This suggests that osteopoiesis may be an essential function of bone marrow cells and confirms the earlier findings of osteogenicity of bone marrow.19,20

ICBG, a non-ATMP, is considered a gold standard in orthopaedic surgery because it is i) osteogenic (contains cells that contribute to osteopoiesis), ii) osteoinductive (contains growth factors, cytokines, and chemokines active in osteopoiesis), and iii) osteoconductive (provides a three dimensional matrix for cells to provide osteopoiesis). Like ICBG, CBMA is also osteogenic and osteoinductive; however, it is not osteoconductive.15,16,21,22 Within bone marrow, there are at least two compartments of stem and progenitor cells that provide osteogenic cells, with more mature pre-osteoblastic cells localizing to the marrow space adjacent to trabecular bone.13

Bone repair via cells only of bone marrow mesenchymal origin has also been questioned. That is, a single marrow cell can have both hematopoietic and osteopoietic progeny, depending upon environmental clues.20,31-33 Bone marrow non-MSCs were shown to have a 10-fold greater bone repopulating activity than MSCs in situations of stress and trauma.10,26 CD34+ cells have been shown to differentiate into functional osteoblasts and fibroblasts in vitro14,34,35 and an in vivo study revealed that fibroblasts are of hematopoietic origins.36 To be sure that the cell investigated in vivo is a hematopoietic stem cell and not a progenitor, secondary BMT assays are used. Via secondary BMT assays, it was found that long-term HSCs contribute to hematopoietic reconstitution and drive osteopoiesis, revealing that HSCs have hematopoiesis and osteopoiesis as essential functions. In bone defects, bone formation was shown to be dependent upon the number of bone marrow cells present because differentiation of stem and progenitor cells toward osteogenesis requires high cell-cell interaction. CBMA provides a method to produce and ensure high concentrations of bone marrow cells for treating bone defects.

Bones are dynamic organs in which replacement of cells occurs through recruited progenitor cells. Bone remodeling takes place in the endosteum region, the site that contains HSC niches.37,38 Marrow-derived stem and progenitor cells enter the circulation as part of host

Table 1. Colony forming units-hematopoietic data by donor and sample type.

| Donor | Sample | Total colonies per 5x10⁴ | CFU-E | CFU-GM | CFU-GEMM |
|-------|--------|-------------------------|-------|--------|----------|
| 1     | Mean   | 235                     | 109   | 101    | 21       |
|       | Std Dev| 21.7                    | 23.9  | 28.5   | 7.8      |
| 2     | Mean   | 194                     | 63    | 117    | 15       |
|       | Std Dev| 29.6                    | 11.6  | 20.7   | 3.4      |
| 3     | Mean   | 153                     | 60    | 86     | 7        |
|       | Std Dev| 22.7                    | 7.1   | 16.9   | 3.8      |

 Colony counts per 5x10⁴ nucleated cells plated. Each donor was analyzed 4 times for a total of 12 samples. Colony forming units-hematopoietic (CFU-h); colony forming units-erythroid (CFU-E); colony forming units-granulopoietic (CFU-GM); colony forming units-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM). Analyses performed by Kevy, Jacobsen (Harvard Medical School) and Mandle (Biosciences Research Associates).

Figure 1. EU regulation 1394/2007. Bone marrow aspirate cells should be classified as a non-advanced therapy medicinal product (ATMP). Concentrated bone marrow aspirate (CBMA) is not (A) a gene therapy medicinal product, (B) a somatic cell therapy medicinal product, (C) a combined ATMP; (D) nor does it fit into the category of a tissue engineered product that has had substantial manipulation and/or the cells/tissues are not used for the same essential function in the recipient as in the donor.
defense, homeostasis, as well as repair and regeneration of injured tissue. The majority of osteoblasts in the human skeleton are found on endocortical surfaces or in intracortical remodeling sites, far from red marrow and trabecular surfaces. This location raised questions as to how the marrow stromal cells can be a source of osteoblasts until it was understood that bone and bone marrow are anatomically and functionally contiguous. Via human cell therapy donor osteoblast studies, it was found that engraftment occurred in transplantation of undifferentiated bone marrow, confirming the reports of osteopoiesis following BMT and that marrow cells are a natural source of osteopoiesis.

Bone and bone marrow are hosts to cells that are interrelated functionally. The stroma system within the bone marrow is not directly involved in hematopoiesis; however, the hematopoietic system and stroma system of the marrow are intertwined. The idea of bone, bone marrow, and blood being intertwined can be dated to at least 1763, and was expanded with the Chronheim hypothesis of 1867 which stated that the bloodstream, and consequently the bone marrow, was the source of the cells involved in healing, including bone. Further evidence of the interrelated functionality of these systems and cells was obtained from data demonstrating that osteoblasts produce many factors required for HSC survival, renewal, and maturation. Additionally, many bone disorders are hematopoietic disorders or disorders of the relationship of hematopoietic and stromal cells (e.g., myelofibrosis with osteosclerosis, Paget’s disease).

Bone marrow cells in the body, ICBG, and CBMA are involved in the essential function of osteopoiesis. To limit the only essential function of bone marrow cells to hematopoiesis does not take into account the non-hematopoietic cells found within bone marrow nor the osteopoietic role of HSCs found within bone marrow, ICBG, and CBMA. Additionally, such a limitation on bone marrow cells does not allow for the intertwining relationship of bone, bone marrow, and blood. Finally, a restrictive view on the essential functions of bone marrow cells does not address the scientific data supporting clinical use of ICBG in orthopedics, which is for treatment of bone defects and not for hematopoietic reconstitution.

Angiogenic and vasculogenic potential

In addition to hematopoiesis and osteopoiesis, bone marrow cells are also active in supporting the vasculature and differentiating into endothelial cells. Bone marrow cells respond to wound healing via various signaling pathways that lead to mobilization of bone marrow EPCs and other cells involved in

Figure 2. Comparison of harvest bone marrow aspirate cells (BMAC) to commercially available mesenchymal stromal cells (MSCs). A,B) BMC sample culture compared with control hMSC’s from known hMSC sample obtained from commercial lab; C,D) Cell morphology changed rapidly when transferred to osteogenic differentiation medium (ODM). Deposition of mineral evident by light microscopy confirmed cells retained potential for osteoblastic differentiation; E,F) Mineral deposition is an indicator of differentiation from the plural potent MSC toward osteogenic cells. Slides of MSC control and BMC cells after 10 days in ODM and stained with Von Kossa silver stain.

Figure 3. Bone marrow cells are involved in wound healing. Bone marrow cells respond to bone defects via the vasculature. The ischemia at the onset of the defect initiates the healing cascade involving bone marrow cells active in the essential functions of osteopoiesis and angiogenesis/vasculogenesis.
the healing cascade. The typical course of response to injury involves posttraumatic ischemia and edema, local inflammation and removal of damaged tissue via phagocytosis, activation of cellular precursors, revascularization of the traumatized region, extracellular matrix as a substrate, increased numbers of regenerating cells, differentiation of the regenerating tissue, morphogenesis of regenerating tissue, and finally, functional restoration. These naturally occurring processes involve bone marrow cells.

Bone marrow contains various progenitor and endothelial cells that are incorporated into sites of reduced vascularity to stimulate angiogenesis and vasculogenesis. Within the injury site, vasculogenesis occurs through local factors stimulating adjacent cells (angiogenesis) and through bone marrow recruited EPCs (vasculogenesis). Consequently, enhancing angiogenesis and vasculogenesis is another essential function of bone marrow cells. To focus upon bone, fracture healing relies upon angiogenesis and vasculogenesis to facilitate callus formation and remodeling; the hemorrhage is inherently angiogenic in composition (Figure 3). These processes involve cells of the bone marrow and it is known that circulating bone marrow hematopoietic stem and progenitor cells differentiate into endothelial cells at sites of vascular remodeling.

All bone maintenance, formation, and healing is linked to vascular supply. Osteoblasts and osteocytes must be within 0.1 mm of a vascular structure to survive and function. Additionally, trabecular bone formation rates have a positive correlation with blood vessel area. Moreover, vascularity and bone are tightly linked in the processes of endochondral ossification, callus formation, and bone regeneration. Bone formation and repair develops heavily upon vascular growth, involving endothelial cells and bone marrow EPCs.

Human CD34+ cells originating from the bone marrow are involved in angiogenesis and vasculogenesis. In a study investigating bone marrow mononuclear cells (BMMNCs) and the CD34+ cell fraction of the BMMNCs, it was found that CD34+ cells significantly enhanced neovascularization and bone repopulation, confirming work that BMMNCs and CBMA demonstrate enhanced neovascularization and functional restoration of induced localized ischemic injury. Blood vessel formation occurs commonly in adults through bone marrow cells and is a major factor in regulating bone healing and several other processes. The essential functions of bone marrow cells must therefore also include enhanced angiogenesis and vasculogenesis.

**Rationale for treating osteonecrosis of the femoral head with concentrated bone marrow aspirate**

Treating bone healing disorders with bone marrow is not a new therapy, nor is the osteogenic nature of bone marrow new knowledge. Phemister presented the idea of creeping substitution in 1930 to describe old bone being gradually absorbed and replaced by new bone. Phemister demonstrated that when there are limited osteogenic elements surviving about the periphery of the necrotic bone, bone absorption may be greatly in excess of bone formation resulting in cavitation. Additionally, Phemister recognized the importance of vessels for the bone and demonstrated that vessel injury may be the cause of some cases of osteonecrosis of the femoral head (ONFH). Vessel injury interferes with blood supply, leading to massive osteonecrosis. Treatment of ONFH has included core decompression since the 1960s when core biopsies were found to immediately reduce pain. Newer approaches may also include vascularized grafting as a means of introducing vascularity. These clinical approaches suggest that improved vascularity may improve core decompression outcomes.

Work relating to Phemister from 342 patients with early stages of ONFH found that common features of ONFH include i) reduction in osteogenic progenitors, ii) increased apoptosis, and iii) altered intramedullary vascularity. The anatomical changes and cellular mechanisms of note are increased apoptosis of osteocytes and inadequate vessels. Non-traumatic ONFH continues to represent a significant challenge in orthopedic surgery and climes through the final common pathway of decreased blood flow to the femoral head that leads to ischemia and death of the bone. It was concluded that core decompression should be supplemented by CBMA to overcome these cellular and vascular issues.

The understanding of the onset of nontraumatic ONFH to be of cellular origin has been formed gradually. Histologic examinations of bone marrow at the site of ONFH demonstrated the pathogenesis of necrosis of hematopoietic cells, endothelial cells, and lipocytes; osteocytes atrophy and die, and a subsequent increase in fatty marrow water content is detectable by magnetic resonance imaging. ONFH represents a gradual degradation of bone marrow; red marrow converts to fatty marrow in the proximal femur and all cell types of bone and marrow are affected. In patients with ONFH, revascularization can occur naturally after the bone dies. Bone marrow cells induced efficient neovascularization in rabbit femoral bone defects and enhanced regeneration of the bone defects. Utilizing CBMA therapy, patients with ONFH have been treated safely and efficaciously. Bone marrow cells are naturally engaged in the formation of new blood vessels so that use of CBMA to address reduced vascularity in ONFH also has clinical utility.

**Discussion**

CBMA is an autologous cell composition that contains the nucleated cells found in bone marrow. Because the process to produce CBMA does not select any subpopulation of bone marrow cells, nor involves any culture expansion steps, it is a total nucleated cell (TNC) composition. As such, CBMA retains its hematopoietic potential (Table 1).

ICBG has three significant disadvantages compared with CBMA. First, the process of ICBG harvesting adds operative time, pain, and blood loss; carries an increased risk of infection, cutaneous nerve damage, and local fracture. Second, the amount of bone available is limited and may be insufficient in many settings. Finally, ICBG has biologic limitation as a cellular graft because the metabolic demands of the graft site often exceed the capacity of the graft delivered since all cells greater than 1 mm to 2 mm of the graft surface die during transplantation. CBMA overcomes the cellular limitation of ICBG.

CBMA results in significant reduction in patient morbidity compared to ICBG because CBMA is obtained through a simple aspiration process rather than surgical resection of the iliac crest to obtain bone and bone marrow and to produce morsels for packing into a bone defect. In contrast, CBMA requires only bone marrow aspiration and centrifugation. It has been shown that CBMA and ICBG are both osteogenic and osteoinductive. Both ICBG and CBMA have been used clinically for the non-hematopoietic essential functions of the cells delivered.

To be regarded as an ATMP requires that cells/tissues be substantially manipulated and/or used for a purpose other than their natural essential function. Osteopoièsis and vasculogenesis have been shown to be natural essential functions of bone marrow cells. Therefore, in accordance with EU regulation 1394/2007, CBMA should be classified and regulated as a non-ATMP.

**Conclusions**

Since bone marrow cells have the natural function of being involved in neovascularization, it begs the question as to why in addition to core decompression CBMA should be added for treating ONFH. There are two important reasons.

In patients with ONFH, the marrow in the
proximal femur has converted to fatty marrow, unable to sustain the creeping substitution of bone noted by Pachimer and others. Because CBMA is the cellular component of ICBG, CBMA addresses the acellularity of the necrotic zone.

Moreover, there is a decrease in blood perfusion in ONFH patients which seems to be the major factor in the disease. It has been shown that CBMA significantly improves perfusion in a murine model. Administration of CBMA provides an autologous cellular augmentation of the potential beneficial effects of core decompression and involves whole bone marrow as a composite of osteoprogenitor, endothelial, and hematopoietic progenitor cells in an environment supporting them in normal physiologic conditions.

The essential function and the mechanism of action of the cell population in CBMA includes more than hematopoietic reconstitution. Osteopoiesis is a critically important essential function of bone marrow cells. The scientific and clinical literature support the conclusion that bone marrow cells naturally involved in hematopoietic reconstitution are also involved in osteopoiesis and angiogenesis/vasculogenesis. Additionally, in 2013, EMA/CAT concluded that CBMA was a non-ATMP for the treatment of osteonecrosis because of three key points: i) non-mesenchymal bone marrow stem/progenitor cells are active in osteoblast formation, ii) bone marrow hematopoietic stem/progenitor cells differentiate in both hematopoietic and osteogenic pathways, and iii) certain stromal cells do not contribute to hematopoietic reconstitution. CBMA is the cellular compartment of ICBG and should be regulated in the same manner as ICBG. As such, CBMA should remain classified as a non-ATMP for the treatment of osteonecrosis.

References

1. European Medicines Agency. Reflection paper on classification of advanced therapy medicinal products. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500169466.pdf.
2. Daley GQ. Hematopoietic stem cells. 3. Armitage JO. Bone marrow transplantation. Essentials of stem cell biology. 2 ed. San Diego: Elsevier; 2009. pp 223-226.
3. Modder U, Khosla S. Skeletal stem/osteoprogenitor cells: current concepts, alternative hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem 2008;103:393-400.
4. Dar A, Gerecht-Nir S, Itskovitz-Eldor J. Human vascular progenitor cells. Stem Cells 2004;22:1176-1183.
5. Siemionow KB, Muschler GF. Principles of bone fusion. In: Herkowitz HN, Garfin SR, Eismont FJ, et al, eds. Rothman-Simeone the spine. 6 ed. Philadelphia: Elsevier; 2009. pp 1130-1158.
6. Mirabet V, Roig RJ, Solves P. Viable hematopoietic progenitor cells in frozen femoral heads from living donors for orthopedic surgery. Transfusion 2011;51:443-4.
7. Abkowitz JL, Robinson AE, Kale S, et al. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003;102:1249-53.
8. Marx RE, Harrell DB. Translational research: The CD34+ cell is crucial for large-volume bone regeneration from the milieu of bone marrow progenitor cells in craniofacial reconstruction. Oral Craniofac Tissue Eng 2012;2:263-71.
9. Vunjak-Novakovic G, Tandon N, Godier A, et al. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev 2010;16:169-87.
10. Chen JI, Hunt P, McElvain M, et al. Osteoblast precursor cells are found in CD34+ cells from human bone marrow. Stem Cells 1997;15:368-77.
lating factor-mobilized CD34-positive progenitor cells using bioscaffold for modality of unhealing bone fracture. Stem Cells 2008;26:1395-405.

35. Ebihara Y, Masuya M, LaRue AC, et al. Hematopoietic origins of fibroblasts: I. In vitro studies of fibroblasts, CFU-F, and fibrocytes. Exp Hematol 2006;34:219-29.

36. LaRue AC, Masuya M, Ebihara Y, et al. Hematopoietic origins of fibroblasts: I. In vivo studies of fibroblasts associated with solid tumors. Exp Hematol 2006;34:208-18.

37. Hsu YC, Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol 2012;13:103-14.

38. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010;327:542-5.

39. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-13.

40. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005;105:2631-9.

41. Friedenstein A. Stromal-hematopoietic interrelationships: Maximov's ideas and modern models. Haematol Blood Transfus 1989;32:159-67.

42. Keyv SY, Jacobson MS, Mandle RJ. Point of care concentration of bone marrow. 2006. Available from: http://www.ors.org/Transactions/52/1738.pdf.

43. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8.

44. Matsumoto T, Kawamoto A, Kuroda R, et al. Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. Am J Pathol 2006;169:1440-57.

45. Matsumoto T, Kuroda R, Mifune Y, et al. Circulating endothelial/skeletal progenitor cells for bone regeneration and healing. Bone 2008;43:434-9.

46. Matsumoto T, Mifune Y, Kawamoto A, et al. Fracture induced mobilization and incorporation of bone marrow-derived endothelial progenitor cells for bone healing. J Cell Physiol 2008;215:334-42.

47. Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol 2002;30:967-72.

48. Carlson BM. Principles of Regenerative biology. Burlington: Academic Press/Elsevier, 2007.

49. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.

50. Hisatome T, Yasunaga Y, Yanada S, et al. Neovascularization and bone regeneration by implantation of autologous bone marrow mononuclear cells. Biomaterials 2005;26:4550-6.

51. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. J Vasc Surg 2007;45:A39-47.

52. Trueta J. The role of the vessels in osteogenesis. J Bone Joint Surg Br 1963;43B:402-18.

53. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 2002;99:9656-61.

54. Oest ME. Dual osteogenic and angiogenic growth factor delivery as a treatment for segmental bone defects. PhD dissertation. Georgia Institute of Technology; 2007.

55. Barou O, Mekraldi S, Vico L, et al. Relationships between trabecular bone remodeling and bone vascularization: a quantitative study. Bone 2002;30:604-12.

56. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005;15:57-63.

57. Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 2003;9:109-17.

58. Yasuhara S, Yasunaga Y, Hisatome T, et al. Efficacy of bone marrow mononuclear cells to promote bone regeneration compared with isolated CD34+ cells from the same volume of aspirate. Artif Organs 2010;34:594-9.

59. Hermann PC, Huber SL, Herrler T, et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant 2008;16:1059-69.

60. Hendrich C, Engelmanar F, Waertel G, et al. Safety of autologous bone marrow aspiration concentrate transplantation: initial experiences in 101 patients. Orthop Rev 2009;1:99-103.

61. Phemister DB. Repair of bone in the presence of aseptic necrosis resulting from fractures, transplantations, and vascular obstruction. J Bone Joint Surg 1930;12:769-87.

62. Steinberg M. The advantages of core decompression for treating avascular necrosis. Univ Pennsylvania Orthop J 2000;13:84-8.

63. Marker DR, Seyler TM, Ulrich SD, et al. Do modern techniques improve core decompression outcomes for hip osteonecrosis? Clin Orthop Relat Res 2008;466:1093-103.  

64. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop 2009;43:40-5.

65. Fessell J. There are many potential medical therapies for atraumatic osteonecrosis. Rheumatology 2013;52:235-41.

66. Seamon J, Keller T, Saleh J, Cui Q. The pathogenesis of nontraumatic osteonecrosis. Arthritis 2012;2012:601763.

67. Gao YS, Zhang CQ. Cytophysiology of osteonecrosis of the femoral head: a mini review. Int Orthop 2010;34:779-82.

68. Abdallah BM, Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 2008;15:109-16.

69. Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am 2009;40:213-21.

70. Gangji V, Hauzeur JP, Schoutens A, et al. Abnormalities in the replicative capacity of osteoblastic cells in the proximal femur of patients with osteonecrosis of the femoral head. J Rheumatol 2003;30:438-51.

71. Laforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint, Bone Spine 2006;73:500-7.

72. Mankin HJ. Nontraumatic Necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-9.

73. Edgar C, Einhorn TA. Treatment of avascular necrosis of the femoral head with drilling and injection of concentrated autologous bone marrow. Tech Orthop 2011;26:2-8.

74. Hernigou P, Beaufage F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002;14-23.

75. Hernigou P, Daltro G, Filippini P, et al. Percutaneous implantation of autologous bone marrow osteoprogenitor cells as treatment of bone avascular necrosis related to sickle cell disease. Open Orthop J 2008;2:62-5.

76. Hernigou P, Mathieu G, Poignard A, et al. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am 2006;88:322-7.

77. Hernigou P, Poignard A, Beaufage F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence
of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005;87:1430-7.

78. Hernigou P, Poignard A, Manicom O, et al. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br 2005;87:896-902.

79. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone 2011;49:1005-9.

80. Gangji V, Hauzeur JP. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique. J Bone Joint Surg Am 2005;87:106-12.

81. Gangji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004;86A:1135-60.

82. Jager M, Hernigou P, Zilkens C, et al. Cell therapy in bone healing disorders. Orthop Rev (Pavia) 2010;2:79-87.

83. Carano RA, Filvaroff EH. Angiogenesis and bone repair. Drug Discovery Today 2003;8:980-9.

84. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;23:1185-9.

85. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004;86A:1541-58.

86. Muschler GF, Mizuta RJ. Connective tissue progenitors: practical concepts for clinical applications. Clin Orthop Relat Res 2002;66-80.

87. Muschler GF, Nakamoto C, Rozic R, et al. Comparison of bone marrow aspiration and bone core biopsy as methods for harvest and assay of human connective tissue progenitor. Paper 41 presented at the 58th Association of Bone and Joint Surgeons; 2006. Buenos Aires, Argentina.

88. McLain RF, Fleming JE, Boehm CA. Muschler GF. Aspiration of osteoprogenitor cells for augmenting spinal fusion: comparison of progenitor cell concentrations from the vertebral body and iliac crest. J Bone Joint Surg Am 2005;87:2655-61.

89. Jin H, Xia B, Yu N, et al. The effects of autologous bone marrow mesenchymal stem cell arterial perfusion on vascular repair and angiogenesis in osteonecrosis of the femoral head in dogs. Int Orthop 2012;36:2589-96.

90. European Medicines Agency: Scientific recommendation on classification of advanced therapy medicine products. Article 17 Regulation (EC) No 1394/2007. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/11/WC500153985.pdf.)